MiNK Therapeutics, Inc.INKTNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank60
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Latest
-2.50
↑ 73% vs avg
Percentile
P60
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-9.42
Historical baseline
PeriodValueYoY Change
2024-2.50-66.7%
2023-1.50+38.7%
2022-2.45+38.6%
2021-3.99+87.5%
2020-31.88-124.5%
2019-14.21-